期刊文献+

3170株临床分离病原菌耐药谱与耐药机制的研究 被引量:20

Drug Susceptibility and Resistant Mechanisms of 3170 Strains of Clinical Isolates
下载PDF
导出
摘要 目的了解医院临床分离病原菌的耐药谱与耐药机制,为合理用药提供依据。方法分离的病原菌用API和Microscan鉴定,药敏用K-B法,数据分析用WHONET5.4软件。结果3170株病原菌中前5位为铜绿假单胞菌、鲍氏不动杆菌、肺炎克雷伯菌、大肠埃希菌、金黄色葡萄球菌,分别为24.3%、10.9%、10.4%、8.9%、8.0%;在G-杆菌中,美罗培南耐药率最低(19.7%),哌拉西林/他唑巴坦耐药率为26.5%,大肠埃希菌和肺炎克雷伯菌产超广谱β-内酰胺酶(ESBLs)阳性率分别为49.1%和33.5%;G+球菌中,万古霉素和替考拉宁敏感率均为100.0%,金黄色葡萄球菌和凝固酶阴性葡萄球菌耐苯唑西林分别为54.2%和82.3%。结论医院临床分离病原菌产ESBLs和耐苯唑西林比率高,应加强抗菌药物的合理使用和采取有效的隔离措施以降低耐药率及多药耐药菌的扩散。 OBJECTIVE To investigate the drug susceptibility of clinical isolates in local region for using antibiotic reasonably. METHODS Totally 3 170 strains of clinical isolates were identified by API and Microscan and tested for drug resistance against antimicrobial agents by K-B method. WHONET5. 4 was applied for analysis. RESULTS The commonly encountered bacteria were Pseudomonas aeruginosa (24.3 %), Acinetobacter baumannii (10.9%), K lebsiella pneumoniae (10.4%), Escherich ia coli (8.9%), and Staphylococcus aureus (SA,8.0%). In Gram-negative isolates, the resistance rate to meropenem was 19. 7%, and to piperacillin-tazobactam was 26.5%. The incidences of E. coli and K. pneumoniae isolates producing extended spectrum beta-lactamases (ESBLs) were 49.1% and 33.5%, respectively. In Gram-positive isolates, the susceptibility rate to vancomycin and teieoplanin both was 100. 0%. The oxacillin resistant rates of SA and coagulase negative Staphylococcus (CNS) were 54. 2.0% and 82.3%. CONCLUSIONS The production ratio of ESBLs and oxaeillin resistance of bacteria in local region are high. It is important to promote the rational use of antimicrobial agents and take effective contaminant methods to reduce resistant rates of bacteria and dissemination of multi-resistant bacteria.
出处 《中华医院感染学杂志》 CAS CSCD 北大核心 2008年第3期422-424,421,共4页 Chinese Journal of Nosocomiology
关键词 病原菌 耐药谱 超广谱Β-内酰胺酶 Pathogen Drug resistance Extended spectrum beta-lactamase
  • 相关文献

参考文献3

二级参考文献20

  • 1National Committee for Clinical Labortory Standards for antimicrobial susceptibility testing[M].Ninth informational standards.Performance Standards M100-S9.Pennsylvania: NCCLS, 1999.1-103.
  • 2Bergogne-Berezin E. Guideline on antimicrobial chemotherapy for prevention and treatment of infections in the ICU. J Chemother, 2001,1: 134-149.
  • 3Goossens H. MYSTIC program: summary of European data from 1997 to 2000. Diagn Microbiol Infect Dis, 2001, 41: 183-189.
  • 4Leblebicioglu H, Gunaydin M, Esen S, et al. Surveillance of antimicrobial resistance in gram-negative isolates from ICU in Turkey:analysis of data from the last 5 years. J Chemother, 2002, 14:140-146.
  • 5Karlowsky JA, Kelly LJ, Thornsberry C , et al. Susceptibility to fluoroquinolones among commonly isolated Gram-negative bacilli in 2000:TRUST and TSN data for the United States. J Autimicrob Agents , 2002,19: 21-31.
  • 6National Committee for Clinical Laboratory Standards. 2002. Performance standards for antimicrobial susceptibility testing. Approved standard M100-S12. National Committee for Clinical Laboratory Standards,Wayne, Pa.2002,1.
  • 7Chanawong A. M' Zali FH, Heritage J, et al. Three cefotaximases,CTX-M-9, CTX-M-13, CTX-M-14, among Enterobacteriaceae in the People's Republic of China. Antimicrob Agents Chemother, 2002, 46:630-637.
  • 8孙长贵,舒建,张丽君,曾贤铭,孙关忠.超广谱β-内酰胺酶大肠埃希菌对19种抗生素的耐药性[J].中华检验医学杂志,2000,23(1):44-44. 被引量:45
  • 9朱戌冬,徐英春,吴伟元,王辉,陈民钧.一种新CTX-M型超广谱β-内酰胺酶及其临床意义[J].中华检验医学杂志,2001,24(4):207-210. 被引量:47
  • 10张勇昌,赵桂兰,赖伟忠.产超广谱β-内酰胺酶病原菌的检测及耐药性监测[J].中华医院感染学杂志,2001,11(6):469-470. 被引量:25

共引文献1025

同被引文献109

引证文献20

二级引证文献166

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部